1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Glioblastoma multiforme (GBM) - Epidemiology Forecast to 2030

Glioblastoma multiforme (GBM) - Epidemiology Forecast to 2030

  • February 2021
  • 171 pages
  • ID: 5962305
  • Format: PDF
  • Delve Insight


Table of Contents

‘Glioblastoma Multiforme (GBM) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Glioblastoma Multiforme (GBM) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Glioblastoma Multiforme (GBM) Understanding
Glioblastoma (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations. There is a remarkable development in GBM because it occurs via a complex network of various different molecular and genetic aberrations, which leads to significant changes in major signaling pathways. GBMs, as they extensively disperse throughout the parenchyma, making maximal surgical resection unattainable and having high level of vascularization, are lethal in nature.

GBM is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced process such as speech and emotions. While GBM is highly locally invasive (invading normal brain tissue), it rarely spreads to other organs beyond the brain. A highly aggressive, fast-growing cancer and treatment is often limited by the tumor location and the ability of a patient to tolerate surgery. Consequently, it is a particularly difficult cancer to treat.

Glioma is considered as the general term which is used to describe the primary brain tumors, and it is also classified to their presumed cell of origin accordingly. The classification includes astrocytic tumors (astrocytoma, anaplastic astrocytoma and glioblastoma), oligodendrogliomas, ependymomas, and mixed gliomas. Gliomas are classified into grade I TO IV on the basis of malignancy that is determined by the histopathalogical criteria. Although the location of GBM is commonly found in the supratentorial region (frontal, temporal, parietal, and occipital lobes), it is rarely located in the cerebellum part. Investigation of genetic and environmental factors of GBM have been done. Prior radiography, decreased susceptibility to allergy, immune factors and immune genes, as well as some nucleotide polymorphisms detected by genomic analysis are all included in the risk factors of the respective disease. The histological classification and tumor grading is a critical step for GBM diagnosis and prognosis.

GBM is a grade IV glioma according to the WHO 2007 classification and is the most common and lethal primary malignancy of the central nervous system. Despite multidisciplinary treatments such as surgery, chemotherapy, and radiotherapy, the median survival time for patients with GBM is only 14.6 months. Due to its high degree of invasiveness, radical tumor resection is not curative. From various experimental evidences it is explained that GBM contains a subpopulation of highly tumorigenic cells (GBM stem cells) from which recurrent GBM is thought to derive, and that GBM has the capacity to differentiate into multiple lineages of tumor genesis.

GBMs can be classified into primary and secondary GBMs:
• Primary GBM occurs de novo without evidence of a less malignant precursor
• Secondary GBM develops from initially low-grade diffuse astrocytoma (WHO grade II diffuse astrocytoma) or anaplastic astrocytoma (Grade III).

Glioblastoma Multiforme (GBM) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Gender-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Type-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Age-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Diagnosed Incident Population based on Primary Site Of Glioblastoma Multiforme (GBM) Tumour and Diagnosed Incident Population based on Histologic Classification of Glioblastoma Multiforme (GBM) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Glioblastoma Multiforme (GBM) Detailed Epidemiology Segmentation
• The total diagnosed incident population of Glioblastoma Multiforme in the 7 major markets was estimated to be 28,259 in 2017. In case of Glioblastoma Multiforme patients in the United States, the diagnosed cases were 14,666 in 2017.
• The total diagnosed incident cases of Glioblastoma Multiforme patients were found to be maximum in males as compared to females in the 7 MM during the study period of 2017–2030.
• In the EU5 countries, the diagnosed incident population of Glioblastoma Multiforme was found to be maximum in Germany with 2,876 cases followed by France with 2,683 cases in 2017. While, Spain accounted for the lowest diagnosed incident population of 1,403 in 2017.
• As per the analysis, Japan had 1,899 diagnosed incident cases of Glioblastoma Multiforme in 2017.

Scope of the Report
• The report covers the descriptive overview of Glioblastoma Multiforme (GBM), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Glioblastoma Multiforme (GBM).
• The report provides the segmentation of the disease epidemiology for the 7MM by Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Gender-specific Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Age-specific Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Type-specific Diagnosed Incident Population of Glioblastoma Multiforme (GBM), etc.

Report Highlights
• Eleven Year Forecast of Glioblastoma Multiforme (GBM)
• 7MM Coverage
• Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM)
• Delvelnsight has analysed type-specific data of GBM according to which there are two main types of Glioblasoma: Primary (de novo) and Secondary Glioblastoma, where the majority of cases (>90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion.
• Diagnosed incidence according to histological classification of Glioblastoma Multiforme tumor was also assessed, which suggests that the conventional GBM type is more prevalent than giant cell GBM (GC-GBM), and gliosarcoma (GS).
• In addition, gener-specific incidence of Glioblastoma Multiforme was also assessed. As per the analysis, GBm is more prevalent in males than in females.
• The epidemiology segmentation also encompasses diagnosed incident population according to primary site of glioblastoma. As per The analyst estimates, it has been found that the primary site of GBM included maximum cases at parietal site, while minimum number of cases were found in unknown and other sites. This trend is clearly evident across all the 7MM countries for the study period 2017–2030.
• The report also encompasses another major segment, i.e., Age-specific Diagnosed Incident Population of Glioblstoma Multiforme (GBM), wherein various age groups have been considered, such as <18, 18–34, 35–64, 65–74 and 75+. It has been found that GBM incidence increases with age peaking at 75–84 years and drops after 85 years.
• Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of GBM. The market is expected to witness a significant positive shift owing to the positive outcomes of the several products during the developmental stage by key players such as Bayer, Diffusion Pharmaceuticals, VBL Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Oncoceutics, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics and Inovio Pharmaceuticals.

Key Questions Answered
• What is the disease risk, burden and unmet needs of Glioblastoma Multiforme (GBM)?
• What is the historical Glioblastoma Multiforme (GBM) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Glioblastoma Multiforme (GBM) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Glioblastoma Multiforme (GBM)?
• Out of the above-mentioned countries, which country would have the highest incident population of Glioblastoma Multiforme (GBM) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The Glioblastoma Multiforme (GBM) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Glioblastoma Multiforme (GBM) market.
• Quantify patient share distribution in the 7MM for Glioblastoma Multiforme (GBM).
• The Glioblastoma Multiforme (GBM) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Glioblastoma Multiforme (GBM) epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Brain Tumor Diagnosis & Treatment Market Research Report by Treatment, by Diagnosis, by Type - United States Forecast to 2025 - Cumulative Impact of COVID-19

  • $ 2249 - $ 1912 - Get 15% off now!
  • January 2021
  • 68 pages

Brain Tumor Diagnosis & Treatment Market Research Report by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Radiosurgery, and Surgery), by Diagnosis (CT Scan, EEG, Molecular Testing, MRI, and ...

  • United States
  • Brain Cancer
  • Industry analysis


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on